- Home
- UONEK vs BRNS Comparison
UONEK vs BRNS Comparison
Compare UONEK & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | UONEK | BRNS |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.9M | 24.1M |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | UONEK | BRNS |
|---|---|---|
| Price | $5.07 | $0.61 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 9.5K | ★ 31.0K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $439,098,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.45 | $0.51 |
| 52 Week High | $9.38 | $1.83 |
Technical Indicators
Market Signals| Indicator | UONEK | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 56.75 | 50.29 |
| Support Level | $4.75 | $0.55 |
| Resistance Level | $5.63 | $0.62 |
| Average True Range (ATR) | 0.34 | 0.04 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 52.78 | 80.00 |
Price Performance
Historical ComparisonAbout UONEK Urban One Inc. Class D
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.